文献速递儿童青少年精神会诊联络精神医学

美国成人医疗兴奋剂使用趋势与模式

Trends and patterns of medical stimulant use by US adults.
PubMed 文献 · Mol Psychiatry · 2026-02-23

基于2018-2023年美国医疗支出面板调查(n=119,138)的成人数据,医疗兴奋剂使用率从1.8%升至2.2%,高收入与就业成人增幅更大;接受ADHD就诊者中使用兴奋剂的比例从81.6%降至74.6%。2021-2023年48.4%的兴奋剂治疗者仅接受面对面行为健康服务,服务模式与ADHD治疗、兴奋剂处方数或苯二氮䓬/阿片类处方无关。

要点

  • 2018-2023年美国成人医疗兴奋剂使用率由1.8%升至2.2%。
  • 高收入与就业成人兴奋剂使用增幅更大。
  • 接受ADHD就诊者中使用兴奋剂比例由81.6%降至74.6%。

核心结论

  • 2018-2023年美国成人医疗兴奋剂使用增加,高收入与就业成人增幅更大,而ADHD就诊者中使用兴奋剂的比例下降。

研究设计与样本

  • 基于2018-2023年医疗支出面板调查(n=119,138)的美国成人数据,按年龄和性别调整后比较不同社会人口学与临床分层中兴奋剂治疗率的2018-2023年差异。

主要发现

  • 医疗兴奋剂使用从2018年的1.8%上升至2023年的2.2%。
  • 家庭收入>400%联邦贫困线者与<100%者相比、就业成人(65岁以上)与非就业成人相比,兴奋剂使用增幅更大。
  • 接受ADHD就诊者中使用兴奋剂的比例从2018年的81.6%下降至2023年的74.6%。
  • 2021-2023年48.4%的兴奋剂治疗者仅接受面对面行为健康服务,30.9%为混合模式,20.7%仅远程医疗。
  • 三种服务模式组间在因ADHD接受兴奋剂的比例、兴奋剂处方数量及苯二氮䓬或阿片类处方上无差异。

临床怎么用

  • 临床应关注高收入与就业成人中兴奋剂使用增加的趋势。
  • ADHD就诊者中兴奋剂治疗比例下降提示需评估处方模式变化。
  • 远程与面对面行为健康服务模式在兴奋剂治疗相关指标上未见差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The authors describe trends in stimulant prescribing to US adults and characterize stimulant-treated adults by use of three modalities: telehealth only, in-person only, or mixed (hybrid) behavioral healthcare. Among US adults in the 2018-2023 Medical Expenditure Panel Survey (n = 119,138), annual stimulant treatment rates are presented with age- and sex-adjusted marginal 2018-2023 differences across sociodemographic and clinical strata. Characteristics of stimulant-treated adults are also presented by reason for stimulant use (attention-deficit/hyperactivity disorder vs. other) and behavioral healthcare modality. Between 2018 and 2023, medical stimulant use increased from 1.8% to 2.2% of adults, including greater increases for adults with household incomes >400% than <100% of the Federal Poverty Level and employed adults than non-employed adults over age 65. However, the percentage of patients receiving ADHD visits who were treated with stimulants declined from 81.6% in 2018 to 74.6% in 2023. In 2021-2023, 48.4% of stimulant-treated patients received all their behavioral healthcare as in-person visits rather than hybrid (30.9%) or telehealth only (20.7%). These three groups did not differ in the percentage who received stimulants for ADHD, the number of stimulant prescriptions they received, or benzodiazepine or opioid prescriptions. In summary, between 2018 and 2023, adult stimulant use increased, particularly among higher-income and employed adults, while the share of ADHD patients treated with stimulants declined. Approximately one-half of stimulant-treated patients received teletherapy, and service modality was not related to ADHD treatment, stimulant prescription counts, or benzodiazepine or opioid prescriptions.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Olfson M, McClellan C, Zuvekas SH, et al. Trends and patterns of medical stimulant use by US adults. Mol Psychiatry. 2026. PMID: 41731001. doi:10.1038/s41380-026-03519-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。